

August 14, 2023

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Monday, August 14, 2023

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board Meeting of the Company held on Monday, August 14, 2023, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2023. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 14, 2023 are enclosed herewith.

The Board Meeting started at 10:30 a.m and concluded at 1:30 p.m.

Please take the same on record.

Thanking you,

For **AstraZeneca Pharma India Limited**


Manasa. R
Company Secretary



AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachanahalli, Outer Ring Road, Bangalore 560 045
 Statement of unaudited financial results for the quarter ended 30 June 2023

Sl No.	Particulars	Rs in lakhs except for earnings per share data			
		3 months ended 30/06/2023	Previous 3 months ended 31/03/2023	Corresponding 3 months ended in the previous year 30/06/2022	Year ended 31/03/2023
		Unaudited	Refer note 3	Unaudited	Audited
1	Income				
	a) Revenue from operations	29,546.68	28,470.35	23,233.29	100,297.08
	b) Other income	810.37	799.72	411.42	2,610.18
	Total income	30,357.05	29,270.07	23,644.72	102,907.26
2	Expenses				
	(a) Cost of materials consumed	1,907.76	2,161.98	1,589.15	8,437.84
	(b) Purchase of stock-in-trade	10,284.95	10,371.27	7,531.44	32,445.89
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,134.12)	(2,669.99)	(782.80)	(4,885.80)
	(d) Employee benefit expense	5,497.48	6,685.98	6,837.12	25,910.26
	(e) Depreciation expense	379.79	424.89	459.18	1,625.00
	(f) Allowance for expected credit loss (net)	(22.46)	41.29	99.00	187.03
	(g) Selling, marketing and distribution expense	2,126.61	1,378.72	1,073.50	5,974.17
	(h) Other expenses	4,161.91	4,516.24	4,089.31	15,735.38
	(i) Finance costs	15.35	8.80	18.62	63.32
	Total expenses	23,217.27	22,919.18	20,914.72	85,473.89
3	Profit before exceptional and extraordinary items and tax (1-2)	7,139.78	6,350.89	2,729.90	17,433.37
4	Exceptional items (Refer Note 4)	-	4,022.91	-	4,022.91
5	Profit before extraordinary items and tax (3-4)	7,139.78	2,327.98	2,729.90	13,410.46
6	Extraordinary items	-	-	-	-
7	Profit before tax (5-6)	7,139.78	2,327.98	2,729.90	13,410.46
8	Tax expense				
	- Current tax	1,746.70	838.18	767.51	3,830.25
	- Deferred tax charge/ (credit)	7.01	(237.32)	(52.87)	(349.04)
	Total tax expense	1,753.71	600.86	714.64	3,481.21
9	Profit after tax (7-8)	5,386.07	1,727.12	2,015.26	9,929.25
10	Other comprehensive income/(loss)				
	A. Items that will not be reclassified to profit or loss				
	Re-measurement gains/(losses) on post employment benefit obligations	60.82	(278.74)	(9.45)	(349.35)
	Income tax effect on above	(15.31)	70.15	2.38	87.92
	Other comprehensive income/ (loss), net of income tax	45.51	(208.59)	(7.07)	(281.43)
	Total comprehensive income for the period (9+10)	5,431.58	1,518.53	2,008.19	9,667.82
11	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00
12	Other Equity	-	-	-	58,368.83
13	Earnings per equity share of Rs 2/- each (basic and diluted)	21.54	6.91	8.06	39.72



AP

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road,
Bangalore 560 045

Statement of unaudited financial results for the quarter ended 30 June 2023

- 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 2 The Company has identified "Healthcare Segment" as its only reportable segment in accordance with the requirements of Ind AS 108, "Operating Segments". Accordingly no segment information has been provided.
- 3 The figures for the quarter ended 31 March 2023 are the balancing figures between the audited figures in respect of the full financial year 31 March 2023 and the published unaudited year to date figures up to the third quarter of the respective financial year i.e., 31 December 2022 which were subjected to review by the statutory auditors.
- 4 Exceptional items for the quarter and year ended 31 March 2023 consists of separation cost amounting to Rs 1,910.32 and Voluntary Retirement Scheme expenses amounting to Rs:2,112.59.
- 5 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 14 August 2023. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 June 2023.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Sanjeev Kumar Panchal
Managing Director

Place: Bengaluru
Date: 14 August, 2023



10

AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter ended 30 June 2023

Sl No.	Particulars	Rs in lakhs except for earnings per share data		
		3 months ended 30/06/2023	Corresponding 3 months ended in the previous year 30/06/2022	Year ended 31/03/2023
		Unaudited	Unaudited	Audited
1	Total income from operations	30,357.05	23,644.82	102,907.26
2	Net profit/(loss) for the period from ordinary activities before tax	7,139.78	2,729.90	13,410.46
3	Net profit/(loss) for the period from ordinary activities after tax	5,386.07	2,015.26	9,929.25
4	Total comprehensive income for the period after tax	5,431.58	2,008.19	9,667.82
5	Equity Share Capital	500.00	500.00	500.00
6	Other Equity	-	-	58,368.83
7	Basic and diluted earnings per share (of Rs 2 each)	21.54	8.06	39.72

Notes:

- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchange websites (www.nseindia.com, www.bseindia.com) and Company's website (www.astrazeneca.com/india).
- The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Sanjeev Kumar Panchal
Managing Director

Place: Bengaluru
Date: 14 August, 2023


Price Waterhouse & Co Chartered Accountants LLP

Independent Auditors' Review Report on the Statement of Unaudited Financial Results

To
The Board of Directors
AstraZeneca Pharma India Limited
Block N1, 12th Floor,
Manyata Embassy Business Park
Rachenahalli Outer Ring Road,
Bengaluru – 560 045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended June 30, 2023, which are included in the accompanying 'Statement of unaudited financial results for the quarter ended 30 June 2023' and the notes thereon (together referred to as the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/E-300009



Prasanna Padar Mahabala
Partner
Membership Number: 206477
UDIN: 23206477BGXCKL3568

Place: Bengaluru
Date: August 14, 2023

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road, Ulsoor
Bengaluru - 560 008
T: +91 (80) 4079 5000, F: +91 (80) 4079 5222

Registered office and Head office: Plot No. 56 & 57, Block DN, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no. LLPIN AAC 4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)